CO6440558A2 - Composiciones farmacéuticas de rendimiento de producto y cumplimiento del paciente superiores - Google Patents

Composiciones farmacéuticas de rendimiento de producto y cumplimiento del paciente superiores

Info

Publication number
CO6440558A2
CO6440558A2 CO11082167A CO11082167A CO6440558A2 CO 6440558 A2 CO6440558 A2 CO 6440558A2 CO 11082167 A CO11082167 A CO 11082167A CO 11082167 A CO11082167 A CO 11082167A CO 6440558 A2 CO6440558 A2 CO 6440558A2
Authority
CO
Colombia
Prior art keywords
compliance
pharmaceutical compositions
product performance
patient superior
superior
Prior art date
Application number
CO11082167A
Other languages
English (en)
Inventor
Ashish Chatterji
Dipen Desai
Harpreet K Sandhu
Navnit Hargovindas Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO6440558A2 publication Critical patent/CO6440558A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona nuevasformulaciones de (2R, 3R, 4R, 5R)-5-(4-amino-2-oxo-2H-pirimidin-1-il)-4-fluoro-2-isobutiriloximetil-4-metil-tetrahidrofurán-3-iI éster de ácido isobutírico e hidroxipropilcelulosaque proporcionan una elevada densidad aparente y untamaño de gránulo reducido más adecuados para unacompresión y flujo mejorados, buena compresión, y perfilesde disolución rápida.
CO11082167A 2009-01-21 2011-06-30 Composiciones farmacéuticas de rendimiento de producto y cumplimiento del paciente superiores CO6440558A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14599909P 2009-01-21 2009-01-21

Publications (1)

Publication Number Publication Date
CO6440558A2 true CO6440558A2 (es) 2012-05-15

Family

ID=42026386

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11082167A CO6440558A2 (es) 2009-01-21 2011-06-30 Composiciones farmacéuticas de rendimiento de producto y cumplimiento del paciente superiores

Country Status (28)

Country Link
US (1) US8222230B2 (es)
EP (1) EP2389164B1 (es)
JP (1) JP5415561B2 (es)
KR (1) KR101331723B1 (es)
CN (1) CN102292075B (es)
AR (1) AR075037A1 (es)
AU (1) AU2010206224B2 (es)
BR (1) BRPI1006924A2 (es)
CA (1) CA2748895C (es)
CL (1) CL2011001764A1 (es)
CO (1) CO6440558A2 (es)
DK (1) DK2389164T3 (es)
EC (1) ECSP11011191A (es)
ES (1) ES2513415T3 (es)
HK (1) HK1164742A1 (es)
IL (1) IL213804A0 (es)
MA (1) MA32969B1 (es)
MX (1) MX2011007771A (es)
NZ (1) NZ593795A (es)
PE (1) PE20120020A1 (es)
PL (1) PL2389164T3 (es)
RU (1) RU2489153C2 (es)
SG (1) SG173001A1 (es)
SI (1) SI2389164T1 (es)
TW (1) TWI414295B (es)
UA (1) UA100937C2 (es)
WO (1) WO2010084041A2 (es)
ZA (1) ZA201104882B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012062691A1 (en) * 2010-11-09 2012-05-18 F. Hoffmann-La Roche Ag Pharmaceutical compositions for treating hcv infections
CN105050708A (zh) 2012-11-14 2015-11-11 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
DE102013215831A1 (de) * 2013-08-09 2015-02-12 Beiersdorf Ag Gelförmiges, alkoholisches Sonnenschutzmittel
WO2016121925A1 (ja) * 2015-01-30 2016-08-04 協和発酵バイオ株式会社 機能性物質を高含有する錠剤及びその製造方法
WO2017140253A1 (zh) * 2016-02-19 2017-08-24 江苏恒瑞医药股份有限公司 一种含有咪唑啉类衍生物的药物组合物
JP6323846B2 (ja) * 2016-04-07 2018-05-16 塩野義製薬株式会社 オピオイドを含有する乱用防止製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0400726A3 (en) * 2001-01-22 2007-05-29 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
JP4408340B2 (ja) * 2002-03-22 2010-02-03 武田薬品工業株式会社 速崩壊性固形製剤
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
KR20080027783A (ko) * 2005-06-22 2008-03-28 다케다 야쿠힌 고교 가부시키가이샤 난용성 활성 성분을 함유하는 정제
JP2008230967A (ja) * 2005-06-23 2008-10-02 Kowa Co 医薬組成物
NZ568909A (en) * 2005-12-09 2011-10-28 Hoffmann La Roche Antiviral 4-fluoro-4-methyl nucleoside prodrugs
BRPI0619890A2 (pt) * 2005-12-14 2011-10-25 Hoffmann La Roche composição farmacêutica e processo para preparação de uma suspensão sólida

Also Published As

Publication number Publication date
SI2389164T1 (sl) 2014-12-31
AU2010206224B2 (en) 2012-12-13
ECSP11011191A (es) 2011-10-31
EP2389164B1 (en) 2014-08-13
WO2010084041A2 (en) 2010-07-29
US20100184716A1 (en) 2010-07-22
US8222230B2 (en) 2012-07-17
DK2389164T3 (da) 2014-09-15
MX2011007771A (es) 2011-08-12
KR20110117683A (ko) 2011-10-27
PE20120020A1 (es) 2012-02-02
RU2489153C2 (ru) 2013-08-10
TWI414295B (zh) 2013-11-11
SG173001A1 (en) 2011-08-29
ZA201104882B (en) 2012-03-28
CA2748895A1 (en) 2010-07-29
CN102292075A (zh) 2011-12-21
AR075037A1 (es) 2011-03-02
IL213804A0 (en) 2011-07-31
EP2389164A2 (en) 2011-11-30
TW201031410A (en) 2010-09-01
CN102292075B (zh) 2013-04-17
NZ593795A (en) 2013-02-22
MA32969B1 (fr) 2012-01-02
AU2010206224A1 (en) 2011-08-25
CA2748895C (en) 2014-05-13
HK1164742A1 (en) 2012-09-28
BRPI1006924A2 (pt) 2016-02-16
ES2513415T3 (es) 2014-10-27
JP2012515739A (ja) 2012-07-12
KR101331723B1 (ko) 2013-11-26
JP5415561B2 (ja) 2014-02-12
RU2011134713A (ru) 2013-03-10
PL2389164T3 (pl) 2015-01-30
WO2010084041A3 (en) 2011-08-18
UA100937C2 (uk) 2013-02-11
CL2011001764A1 (es) 2012-01-20

Similar Documents

Publication Publication Date Title
CO6440558A2 (es) Composiciones farmacéuticas de rendimiento de producto y cumplimiento del paciente superiores
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
WO2013185112A8 (en) Pharmaceutical compositions for the treatment of cftr -mediated disorders
AR084473A1 (es) Composiciones farmaceuticas de (r) 1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropanecarboxamida
MY161088A (en) Agonists of gpr40
CL2008003827A1 (es) Composicion para tabletas de desintegracion oral que comprende al menos una droga ( temazepam), 0,5-3% de un polimero aglutinanete para odt, un alcohol de azucar y/o sacarido, y un desintegrante; metodo para prepararla; util para tratar una enfermedad o condicion como un trastorno del sueño en pacientes con disfagia..
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
IN2012DN01435A (es)
EP2535058A3 (en) Stabilization of vaccines by lyophilization
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
CL2013002241A1 (es) Compuestos derivados de (4,4´-bifeniilbis(1h-imidazol-4,2-diil)-2,1-pirrolidindiil((1s)-1-((2r,6r)-2,4-dimetilltetrahidro-2h-piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo, inhibidores del vhc; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso para tratar una infeccion por vhc.
TN2012000515A1 (en) Pharmaceutical compositions of co-crystals of tramadol and coxibs
IN2015DN02907A (es)
MX2009007784A (es) Composiciones de tiacumicinas estables.
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
SV2011003852A (es) Particulas inhalables que comprenden tiotropio
EA201290985A1 (ru) Пероральные ветеринарные фармацевтические и нутрицевтические композиции
EA201200604A1 (ru) Фармацевтические субстанции на основе митохондриальноадресованных антиоксидантов
WO2011101863A3 (en) Extended release pharmaceutical compositions of lacosamide
MX2014003261A (es) Formulaciones de acido ciclopropancarboxilico de {2-[(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-3-oxo-2 ,3-dihidro-1h-isoindol-4-il}-amida.
CL2012003521A1 (es) Derivado piperidino (r)-n-((r)-1-((3s-4s)-4-(4-clorofenil)-3,4-dihidroxi-3-metilpiperidin-1-il)-3-metil-1-oxobutan-2-il)-3,3-difluorociclopentanocarboxamida, modulador receptor quimiocinas; composicion farmaceutica; y uso del compuesto y su composicion en enfermedades inflamatorias y autoinmunitarias, entre otras.
CO6341474A2 (es) Formas solidas de (1r,2s,3r)-1-(2-isoxazol-3-il)-1h-imidazol-4-il) butano-1,2,3,4-tetraol y metodos para su uso
WO2010099510A3 (en) Amino acid-based compounds, their methods of use, and methods of screening
EA201691034A1 (ru) Композиции в твердой форме с замедленным высвобождением для перорального введения

Legal Events

Date Code Title Description
FC Application refused